Tag: MONOGRAPH

  • Phenibut

    GABA-B agonist / phenyl-GABA

    A Soviet-developed phenyl-substituted GABA analog with GABA-B receptor agonism, used clinically in Russia for anxiety and sleep with documented dependence liability.

    Abstract

    Phenibut (4-amino-3-phenyl-butanoic acid; CAS 1078-21-3; molecular formula C10H13NO2; molecular weight 179.22) is a phenyl-substituted GABA analog developed in the Soviet Union in the 1960s at the Herzen State Pedagogical University. The phenyl substitution at the 3-position confers blood-brain barrier permeability that GABA itself lacks. Phenibut is approved in Russia, Belarus, Kazakhstan, and Latvia as Phenibut, Noofen, and Anvifen for anxiety, insomnia, asthenia, and post-traumatic stress disorder. Mechanism is primarily GABA-B receptor agonism (similar to baclofen) with secondary effects on voltage-gated calcium channels at higher doses. The (R)-enantiomer is the active component. Pharmacokinetics: plasma half-life 5 to 6 hours; rapid oral absorption. Phenibut has documented dependence liability with chronic high-dose use; withdrawal syndrome includes anxiety, insomnia, tremor, and rebound symptoms. The compound is sold as a research chemical/dietary supplement in the United States though regulatory classification is increasingly restrictive in some states. Investigators should be aware of the dependence potential and avoid daily dosing schedules.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Follistatin 315

    Myostatin antagonist / follistatin isoform

    A 315-residue isoform of follistatin with reduced heparin binding and longer plasma half-life than follistatin 344.

    Abstract

    Follistatin 315 is a 315-residue isoform of follistatin produced by alternative splicing of the FST gene, lacking the C-terminal acidic region present in follistatin 344. The compound has reduced heparin binding (which improves plasma circulation; follistatin 344 is largely tissue-bound through cell surface heparan sulfate) and a longer plasma half-life. Like follistatin 344, the compound antagonizes myostatin (GDF-8) and activin A. The compound is sold as a research peptide. There is no formal clinical development record. Investigational doses parallel follistatin 344; safety considerations are similar.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Cordyceps (Cordyceps militaris / sinensis)

    Medicinal mushroom / cordycepin source

    A parasitic fungus traditionally used in Chinese medicine for fatigue and physical performance, characterized by cordycepin (3′-deoxyadenosine) bioactivity.

    Abstract

    Cordyceps (Cordyceps militaris and the related Cordyceps sinensis / Ophiocordyceps sinensis) are parasitic fungi traditionally used in Chinese medicine for energy, endurance, and respiratory function. The active constituents include cordycepin (3′-deoxyadenosine), polysaccharides, and ergosterol derivatives. Cordyceps militaris is now the predominant commercial form due to the rarity and protected status of wild C. sinensis. Modest cardiovascular effects (improved exercise tolerance, attenuated blood pressure response) have been documented in randomized trials. Mechanism is incompletely characterized; cordycepin has documented adenosine receptor effects and modest anticancer activity.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Thymopentin

    Synthetic pentapeptide of thymopoietin

    A synthetic pentapeptide fragment (residues 32-36) of thymopoietin marketed in Europe and Asia for immunomodulation in chronic infections and autoimmune disease.

    Abstract

    Thymopentin (Timunox, TP-5; Arg-Lys-Asp-Val-Tyr; CAS 69558-55-0; molecular weight 679.78) is a synthetic pentapeptide corresponding to residues 32-36 of thymopoietin, a thymic hormone. The fragment retains the immunomodulatory activity of full-length thymopoietin. The compound is approved in Italy and several Asian countries for primary immunodeficiency, hepatitis B, atopic dermatitis adjunct, and autoimmune disease support. Mechanism includes T-cell maturation, NK cell modulation, and cytokine balance effects. Administered subcutaneously.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • L-DOPA (Levodopa)

    Dopamine precursor

    The immediate precursor of dopamine and the principal pharmacological treatment for Parkinson disease, FDA-approved in combination with carbidopa.

    Abstract

    L-DOPA (levodopa, L-3,4-dihydroxyphenylalanine; CAS 59-92-7; molecular formula C9H11NO4; molecular weight 197.19) is the immediate precursor of dopamine in the catecholamine biosynthesis pathway. The compound is FDA-approved in combination with carbidopa (Sinemet) or benserazide for Parkinson disease. L-DOPA is the principal symptomatic treatment for Parkinson disease and remains the gold standard despite long-term complications including motor fluctuations and dyskinesia. The compound is also extracted naturally from Mucuna pruriens.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Magnesium Taurate

    Magnesium-taurine chelate

    A magnesium chelate with taurine emphasized for cardiovascular applications based on combined magnesium and taurine effects.

    Abstract

    Magnesium taurate is a chelated magnesium salt where magnesium is bound to taurine (2-aminoethanesulfonic acid). The compound is emphasized for cardiovascular applications based on the combined effects of magnesium (membrane stabilization, vascular smooth muscle relaxation) and taurine (osmolyte, calcium handling, cardiac membrane effects). The compound has high bioavailability similar to other amino acid chelates.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Astaxanthin

    Carotenoid antioxidant

    A red carotenoid pigment from Haematococcus pluvialis algae characterized by potent antioxidant activity and high oral bioavailability.

    Abstract

    Astaxanthin (CAS 472-61-7; molecular formula C40H52O4; molecular weight 596.84) is a red carotenoid pigment produced by Haematococcus pluvialis (the algal source of most commercial astaxanthin) and present in seafood (salmon, krill, shrimp). The compound is one of the most potent natural antioxidants, exceeding the radical-quenching capacity of vitamin C, vitamin E, and beta-carotene in many in vitro assays. Pharmacology includes direct radical scavenging, NRF2 pathway activation, and anti-inflammatory effects through NF-kB inhibition. Clinical applications include skin photoprotection (modest evidence), cardiovascular function, and exercise recovery.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Escitalopram

    S-enantiomer SSRI

    The (S)-enantiomer of citalopram; the active component of the racemate marketed as a separate antidepressant with improved tolerability.

    Abstract

    Escitalopram (S-(+)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile; CAS 128196-01-0; molecular formula C20H21FN2O; molecular weight 324.39) is the (S)-enantiomer of citalopram, marketed as Lexapro by H. Lundbeck and Forest Pharmaceuticals after FDA approval in 2002. SERT affinity is approximately 1 nM; selectivity for SERT over NET and DAT is the highest of any clinical SSRI. The active enantiomer is responsible for essentially all SERT inhibitory activity in racemic citalopram; the (R)-enantiomer attenuates (S) binding through an allosteric SERT interaction, so removing it produces a small but measurable increase in serotonergic efficacy per milligram. Plasma half-life is approximately 27 to 32 hours, slightly shorter than racemic citalopram. Hepatic metabolism via CYP2C19 with secondary CYP3A4 and CYP2D6 contribution. The compound exhibits the QTc prolongation profile of racemic citalopram but with a cleaner adverse event signature owing to the absence of the (R)-enantiomer. Approved for major depressive disorder and generalized anxiety disorder. Used as a high-purity SERT-selective reference compound in mechanism studies.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Selegiline

    Selective irreversible MAO-B inhibitor

    A propargyl phenethylamine MAO-B inhibitor used in Parkinson disease and at higher doses in depression via MAO-A engagement.

    Abstract

    Selegiline ((R)-N-methyl-N-(1-phenylpropan-2-yl)prop-2-yn-1-amine; CAS 14611-51-9; molecular formula C13H17N; molecular weight 187.28) is an irreversible propargyl-substituted MAO-B inhibitor developed by Joseph Knoll in Hungary in the 1960s. Metabolites include amphetamine and methamphetamine, contributing to subjective alertness and complicating drug screening. Used as a reference MAO-B selective inhibitor in Parkinson research and as a transdermal MAOI in depression studies.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Sodium Valproate

    Branched-chain fatty acid anticonvulsant / mood stabilizer

    A simple branched-chain fatty acid with broad anticonvulsant activity and mood-stabilizing efficacy in bipolar disorder.

    Abstract

    Sodium valproate (sodium 2-propylpentanoate; CAS 1069-66-5; molecular formula C8H15NaO2; molecular weight 166.20) is a branched-chain fatty acid anticonvulsant first characterized as bioactive in 1962 (incidentally, while serving as a solvent in pharmacological screening at Lyon). Approved by the FDA in 1978 (Depakote, the divalproex sodium delayed-release form). Mechanism is multifactorial: GABA transaminase inhibition increases brain GABA; sodium channel blockade reduces neuronal hyperexcitability; T-type calcium channel inhibition supports anti-absence activity; histone deacetylase (HDAC) inhibition modifies gene expression with neuroprotective and possibly disease-modifying implications in bipolar disorder. Plasma half-life is 9 to 16 hours; metabolism is via beta-oxidation, omega-oxidation, and glucuronidation. Approved indications include all major seizure types (partial, generalized tonic-clonic, absence, myoclonic), bipolar I disorder mania, and migraine prophylaxis. The principal limitation is teratogenicity (neural tube defects, cognitive deficits in offspring) requiring strict avoidance in pregnancy and women of childbearing age. Hepatotoxicity, pancreatitis, and hyperammonemia are recognized adverse events. Used as the canonical broad-spectrum anticonvulsant and HDAC inhibitor reference.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.